Infantile Arterial Calcification and Subsequent Hypophosphatemia Due to ENPP1 mutation
A case followed through to adulthood

Munier A Nour1, Mark Inman1, Terra Arnason2

1) Division of Pediatric Endocrinology; Department of Pediatrics; University of Saskatchewan
2) Division of Endocrinology; Department of Medicine; University of Saskatchewan

Introduction

• Infantile Arterial Calcification (IAC) is a rare and frequently lethal condition.
• Children who survive the infantile period may develop fibroblast-growth-factor 23 (FGF23) mediated hypophosphatemia and rickets when IAC is due to mutations in the ENPP1 gene.

Case Progression

• Term female was born with extensive calcifications noted in utero involving the coronary arteries and cardiac valves.
• Family history of previous sibling death at 4 months due to extensive vascular calcifications.
• Genetic testing as an adult confirmed compound heterozygous pathogenic mutations of ENPP1 gene:
  - c.2191del, p.(Asn731Ilefs*5); and
  - c.583T>C, p.(Cys195Arg).
• Treated by 1 week of life with a first-generation bisphosphonate (Etidronate).
• Developed Rickets by 4 months of age.
  - Ca 2.7 mM (2.2 – 2.8 mM)
  - PO4 1.10 mM (1.25 – 2.1 mM)
  - ALP 2117 U/L (150 – 450 U/L)
  - PTH 1.5 pM (1.3 – 7.6 pM)
• Rickets initially attributed to Etidronate therapy leading to dose reduction then discontinuation at 2.5 yrs.
• Hypophosphatemia persisted
  - Ca 2.6 mM (2.2 – 2.6 mM)
  - PO4 1.07 mM (1.30 – 1.70 mM)
  - ALP 647 U/L (150 – 300 U/L)
  - PTH 118 pm (1.3 – 7.6 pM)
  - 1,25(OH)2D3 70 pm (40-140 pM)
• Phosphate & Rocaltrol initiated by 4yrs.
• During puberty, new calcifications developed with worsening renal artery stenosis, SMA/IMA/Celiac artery stenosis and Aortic valve calcifications. Hypophosphatemia therapy stopped.
  - Ca 2.35 mM (2.1 – 2.6 mM)
  - PO4 0.59 mM (0.87 – 1.45 mM)
  - ALP 142 U/L (30 – 110 U/L)
  - PTH 8 pm (1.3 – 6.8 pM)
  - 1,25(OH)2D3 105 pm (60-160 pM)
• Calcifications remained stable as an adult until the initiation of an oral contraceptive pill (OCP), with acute worsening of calcifications noted. Serum phosphate increased from ~0.4 mM pre-OCP to 0.75 mM.
• Recently, off-label therapy with Acetazolamide is being trialed to reduce systemic calcifications through renal excretion.

Discussion

• Patients with ENPP1 mutations that survive infancy present a unique balance between bone hypomineralization that paradoxically coexists with extraskeletal calcifications.
• Our patient developed painful and compromising calcium deposition during periods of elevated estrogen levels (neonate, puberty, OCP initiation) leading the authors to query if estrogen may modulate extra-skeletal calcifications.
• Population studies have demonstrated a reduction in FGF23 levels associated with estrogen hormone replacement.
• While a great deal remains to be delineated in FGF23 regulation, clear differences have been observed in infancy, adolescence and between sexes that suggest estrogen may contribute in this case, and may offer insights into mineral homeostasis.
• Experimental therapies to minimize calcium deposits and reverse systemic calcifications in IAC and other conditions have been proposed; including: first-generation bisphosphonates, sodium thiosulfate and acetazolamide.

Conclusion

• IAC is a rare and often fatal condition in infancy, such that our adult survivor is allowing rare insights into clinical outcomes through to full maturation.
• Here, we present an adult survivor of IAC arising from a proven compound heterozygous ENPP1 mutations, allowing a unique look at possible exacerbating and mitigating factors for calcium-phosphate deposition.
• The apparent exacerbation of calcification formation during times of increased estrogen suggest a possible estrogen-signaling mechanism for future investigation.
• Further analysis of the disease course may offer insights into the underlying mechanisms of mineral homeostasis and opportunities for future therapeutic targets.

References